Previous Close | 65.28 |
Open | 65.22 |
Bid | 71.12 x 1000 |
Ask | 71.74 x 44000 |
Day's Range | 65.20 - 65.67 |
52 Week Range | 25.38 - 87.65 |
Volume | 553,242 |
Avg. Volume | 7,550 |
Market Cap | 81.713B |
Beta | 0.84 |
PE Ratio (TTM) | 9.84 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.03 (4.59%) |
Ex-Dividend Date | 2018-05-11 |
1y Target Est | N/A |
Investors are happy the biotech ended a lawsuit hanging over its head.
The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...
Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.
The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.
Advent is preparing to take on a drugmaker it tried and failed to buy.
Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.
Private equity firm Advent has confirmed that it has entered into exclusive negotiations to buy Zentiva, Sanofi’s European generics business, for €1.91bn. A statement from the two firms on Tuesday said ...
Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.
Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...
Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.
French healthcare and drugs group Sanofi (SASY.PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday. Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio. Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Barclays creates venture capital-style unit https://on.ft.com/2qCe467 ...
Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.
Advent International, the US buyout group, is close to clinching a deal to buy the European generics business of Sanofi , according to two people familiar with the transaction. The news comes after the ...
Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi as it tries to fend off competition from both trade and financial buyers, ...
Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi , as it tries to fend off competition from both trade and financial buyers, ...
French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area. Sanofi's new investment will finance the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The new facility would allow its Sanofi Pasteur division to meet the growing demand of five-component acellular pertussis (5-acP) antigen, the company added.
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.
Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.
French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.